This site uses cookies. By using this site you agree to receiving cookies. View Policy.

Successfully funded
Capital at risk
overfunded
Cell Guidance Systems
167%
Raised
£836,370
Investors
862
Target
£500,000
Equity
8.29%
Pre-money valuation
£9,250,000

Cell Guidance Systems is developing a patented technology to unlock the medical potential of growth factor proteins. PODS enables proteins to treat diseases, such as Parkinson's disease and osteoarthritis, by improving their delivery to the disease site. The technology addresses multi-$bn markets.

  • Unique patented technology proven in animal models of disease
  • Aiming to address multiple global healthcare issues affecting millions
  • Working with University of Cambridge on lead osteoarthritis programme
  • Medical research reagent division, generating >£1m in revenues in 2017
Information Due to ongoing overfunding momentum, the pitch has been extended and will now expire at midnight on Friday 1st June 2018.

Idea

Most of the world's top-selling drugs are proteins. Humira alone generated sales >$18bn in 2017 (www.statista.com).

Cell Guidance Systems, based in Cambridge at the heart of the UK biotech industry, is developing PODS (Polyhedrin Delivery System), a platform technology for sustained growth factor delivery protected by exclusively licensed patents. PODS has the potential to transform medical care for many common diseases including osteoarthritis, neurodegenerative disease (such as Parkinson’s disease and motor neuron disease), wound healing, eye disease, and cancer. PODS research also shows potential for the delivery of vaccines. Our lead programme for osteoarthritis is being developed with the University of Cambridge.

Cell Guidance Systems generated revenues of >£1m in revenue in 2017 when consolidated with revenue from its wholly owned US subsidiary, (operating at a £90k loss). Our objective is to become a leading global therapeutic protein delivery company, with therapeutic products in clinics within 3 years.

Why is delivery important?

Growth factors, a particularly potent class of proteins, guide cells to regenerate damaged tissue, but most need to be targeted by precise surgical delivery to avoid harmful side effects. Since daily surgery isn't practical and growth factors can be slow-acting and fragile, a technology providing sustained release of stabilized protein is required.

THE MATERIALS YOU ARE SEEKING TO ACCESS ARE BEING MADE AVAILABLE BY THE COMPANY RAISING FINANCE AS IDENTIFIED ABOVE (THE "COMPANY") IN GOOD FAITH AND FOR INFORMATION PURPOSES ONLY AND SUBJECT TO THESE TERMS AND CONDITIONS.  CROWDCUBE CAPITAL LTD IS AUTHORISED BY THE FCA AND CARRIES OUT DUE DILIGENCE ON EACH COMPANY THAT LISTS ON CROWDCUBE AS SET OUT HERE.
 
This investment opportunity is not an offer to the public and is only available to registered members of Crowdcube.com who have qualified and categorised themselves as able to invest.  The investment opportunity is not directed at persons located in the United States, Canada or Japan. Any person resident outside the United Kingdom who wishes to view these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict access.
In particular, unless otherwise determined by the Company and permitted by applicable law and regulation, it is not intended, subject to certain exceptions, that any offering of the securities mentioned in such materials (the "Securities") by the Company would be made, or any documentation be sent in or into, the United States, Canada or Japan.  There will be no public offering of the Securities in the United States.
 
In order to access the pitch you must first become a qualifying member of Crowdcube on the basis of your status as either (i) self-certified ‘high net worth investor’, (ii) certified ‘sophisticated investor’, (iii) self-certified as a ‘sophisticated investor’ or (iv) certified as a ‘restricted investor’, in each case in accordance with the FCA’s Conduct of Business Sourcebook Chapter 4.7.  Potential investors are encouraged to "cross examine" the Company by interactive due diligence and use of the available online forums to bring the "wisdom of the crowd" to bear.  Accessing the pitch also means you agree to Crowdcube’s most recent website terms and conditions and investor terms and conditions, which include Crowdcube's limitation of liability.
 
If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.  Crowdcube’s or the Issuer’s press announcements and this information page do not constitute an offer to sell securities of the Company.  Further, it does not constitute a recommendation by the Company, Crowdcube or any other party to sell or buy securities in the Company.
 
By registering or logging into Crowdcube.com to view the investment opportunity, you certify that you are legally entitled to view the investment opportunities, are an authorised investor and you agree to all applicable terms and conditions on this website, including this disclaimer.

To see the rest of the Cell Guidance Systems pitch, join now.
It’s free, quick and easy.

Join

Already registered? Log in

To see the rest of the Cell Guidance Systems pitch, join now.
It’s free, quick and easy.

Cell Guidance Systems

Join to read more information about the Cell Guidance Systems team, documents, and what other investors are saying about the pitch.

If you choose to invest we won’t take your money until the pitch closes and you can cancel your investment at any time.

Crowdcube is a leading investment crowdfunding platform

Successfully Invested
£689m+
Registered Investors
735k+